NYSE:MCKMcKesson Competitors & Alternatives

McKesson (NYSE:MCK) and Celgene (NASDAQ:CELG) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares McKesson and Celgene's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for McKesson and Celgene, as reported by MarketBeat.com.

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Celgene has a consensus price target of $105.60, indicating a potential downside of 2.44%. Given McKesson's stronger consensus rating and higher probable upside, equities research analysts plainly believe McKesson is more favorable than Celgene.

Risk and Volatility

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Celgene has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Institutional & Insider Ownership

79.2% of McKesson shares are owned by institutional investors. Comparatively, 71.7% of Celgene shares are owned by institutional investors. 0.3% of McKesson shares are owned by insiders. Comparatively, 0.4% of Celgene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares McKesson and Celgene's top-line revenue, earnings per share (EPS) and valuation.

Celgene has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

McKesson (NYSE:MCK) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares McKesson and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for McKesson and Vertex Pharmaceuticals, as reported by MarketBeat.com.

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Vertex Pharmaceuticals has a consensus price target of $285.1154, indicating a potential downside of 3.17%. Given McKesson's higher probable upside, equities research analysts plainly believe McKesson is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

79.2% of McKesson shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.3% of McKesson shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares McKesson and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats McKesson on 11 of the 15 factors compared between the two stocks.

McKesson (NYSE:MCK) and Becton Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares McKesson and Becton Dickinson and's net margins, return on equity and return on assets.

Dividends

McKesson pays an annual dividend of $1.64 per share and has a dividend yield of 1.1%. Becton Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.2%. McKesson pays out 11.0% of its earnings in the form of a dividend. Becton Dickinson and pays out 27.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. McKesson has increased its dividend for 7 consecutive years and Becton Dickinson and has increased its dividend for 48 consecutive years. Becton Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent ratings for McKesson and Becton Dickinson and, as reported by MarketBeat.com.

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Becton Dickinson and has a consensus price target of $276.0667, indicating a potential upside of 7.26%. Given McKesson's stronger consensus rating and higher probable upside, equities research analysts plainly believe McKesson is more favorable than Becton Dickinson and.

Volatility & Risk

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Institutional and Insider Ownership

79.2% of McKesson shares are held by institutional investors. Comparatively, 85.4% of Becton Dickinson and shares are held by institutional investors. 0.3% of McKesson shares are held by insiders. Comparatively, 0.1% of Becton Dickinson and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares McKesson and Becton Dickinson and's revenue, earnings per share (EPS) and valuation.

Becton Dickinson and has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Becton Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton Dickinson and beats McKesson on 9 of the 17 factors compared between the two stocks.

McKesson (NYSE:MCK) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for McKesson and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

McKesson currently has a consensus price target of $172.7143, indicating a potential upside of 20.76%. Regeneron Pharmaceuticals has a consensus price target of $573.2593, indicating a potential downside of 7.67%. Given McKesson's stronger consensus rating and higher probable upside, equities research analysts plainly believe McKesson is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

McKesson has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares McKesson and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares McKesson and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

79.2% of McKesson shares are owned by institutional investors. Comparatively, 68.1% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of McKesson shares are owned by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats McKesson on 9 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Intuitive Surgical and McKesson, as reported by MarketBeat.

Intuitive Surgical currently has a consensus target price of $571.1176, indicating a potential downside of 0.83%. McKesson has a consensus target price of $172.7143, indicating a potential upside of 20.76%. Given McKesson's stronger consensus rating and higher possible upside, analysts plainly believe McKesson is more favorable than Intuitive Surgical.

Volatility & Risk

Intuitive Surgical has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Valuation & Earnings

This table compares Intuitive Surgical and McKesson's gross revenue, earnings per share and valuation.

Intuitive Surgical has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and McKesson's net margins, return on equity and return on assets.

Institutional & Insider Ownership

87.2% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 79.2% of McKesson shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 0.3% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Intuitive Surgical beats McKesson on 9 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Stryker and McKesson, as reported by MarketBeat.

Stryker currently has a consensus target price of $215.20, indicating a potential upside of 20.97%. McKesson has a consensus target price of $172.7143, indicating a potential upside of 20.76%. Given Stryker's higher possible upside, analysts plainly believe Stryker is more favorable than McKesson.

Volatility & Risk

Stryker has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stryker and McKesson's top-line revenue, earnings per share (EPS) and valuation.

Stryker has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.3%. McKesson pays an annual dividend of $1.64 per share and has a dividend yield of 1.1%. Stryker pays out 27.8% of its earnings in the form of a dividend. McKesson pays out 11.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 9 consecutive years and McKesson has increased its dividend for 7 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Stryker and McKesson's net margins, return on equity and return on assets.

Institutional and Insider Ownership

71.2% of Stryker shares are owned by institutional investors. Comparatively, 79.2% of McKesson shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 0.3% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Stryker beats McKesson on 11 of the 17 factors compared between the two stocks.